<DOC>
	<DOCNO>NCT01858077</DOCNO>
	<brief_summary>To evaluate efficacy performance all-comers contemporary population ABSORB bioresorbable vascular scaffold ( BVS ) strategy versus XIENCE family ( XIENCE PRIME XIENCE Xpedition ) everolimus elute coronary stent system treatment coronary lesion .</brief_summary>
	<brief_title>Amsterdam Investigator-initiateD Absorb Strategy All-comers Trial</brief_title>
	<detailed_description>The AIDA trial prospective , randomize ( 1:1 ) , active control , single blind , four-center , all-comers , non-inferiority trial . A total 2690 subject enrol broad inclusion limit exclusion criterion . The study population include simple complex lesion , well stable acute coronary syndrome patient . The follow-up continue 5 year include clinical endpoint characteristic .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Subject acceptable candidate treatment drugeluting stent accordance applicable guideline percutaneous coronary intervention Instructions Use ABSORB BVS strategy XIENCE family . Subject able verbally confirm understand risk , benefit treatment alternative receive ABSORB BVS strategy he/she his/her legally authorize representative provide write informed consent prior Clinical Investigation related procedure , approve appropriate Ethics Committee . Subject young 18 year age Subject true bifurcation lesion priori two scaffold/stent strategy plan . Unsuccessful predilation one plan lesion treat . Planned treatment instent restenosis previously place metallic stent . Subject one lesion plan treat scaffold/stent diameter size small 2.5 mm great 4.0 mm . Subject one lesion plan treat stent/scaffold length great 70 mm and/or overlap four scaffolds/stents . Subject know hypersensitivity contraindication aspirin , heparin bivalirudin , antiplatelet medication specify use study ( clopidogrel , prasugrel ticagrelor , inclusive ) , everolimus , poly ( Llactide ) , poly ( DLlactide ) , cobalt , chromium , nickel , tungsten , acrylic fluoro polymer contrast sensitivity adequately premedicated . Subjects pregnant nursing subject plan pregnancy period 2 year follow index procedure . ( Female subject childbearing potential must negative pregnancy test do within 28 day prior index procedure contraception must use participation trial ) Subjects limited life expectancy le one year . Subjects factor impede clinical followup ( e.g . fix abode ) . Subject already participate another clinical investigation yet reach primary endpoint . Subject belong vulnerable population ( per investigator 's judgment , e.g. , subordinate hospital staff sponsor staff ) subject unable read write .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>